Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Radiesse® Safety Study For the Treatment of Hands
NCT02904096 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.
Conditions Studied
Interventions
- DEVICE Radiesse injectable implant and 2% lidocaine HCL
Study Locations (9)
California
- Merz Investigative Site #0010393 — Sacramento
- Merz Investigative Site #0010321 — San Diego
- Merz Investigative Site #0010358 — Vista
- Merz Investigative Site #0010099 — West Hollywood
New York
- Merz Investigative Site #0010405 — New York
- Merz Investigative Site #0010406 — New York
Texas
- Merz Investigative Site #0010322 — Austin
- Merz Investigative Site #0010125 — Plano
Washington
- Merz Investigative Site #0010392 — Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2016-06-10 |
| Est. Completion | 2019-01-09 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02904096
The ClinicalTrials.gov registry entry for NCT02904096 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Volume Loss in the Dorsum of the Hand appearing as the primary indexed condition, and to 1 intervention — of which Radiesse injectable implant and 2% lidocaine HCL is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02904096 reports 9 study locations spanning 4 distinct geographic areas — top geographies include California, New York, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02904096 about?
NCT02904096 is a clinical study titled "Radiesse® Safety Study For the Treatment of Hands". The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.
What is the current status of trial NCT02904096?
This trial is currently completed. It is a NA study. The enrollment target is 256 participants. The study started on 2016-06-10. Estimated completion is 2019-01-09.
What conditions does trial NCT02904096 study?
This clinical trial studies the following conditions: Volume Loss in the Dorsum of the Hand. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02904096?
The interventions under investigation include: Radiesse injectable implant and 2% lidocaine HCL (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02904096?
This trial is sponsored by Merz North America, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02904096 being conducted?
This trial has 9 study locations across California, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.